MannKind Corporation (NASDAQ:MNKD), a biopharmaceutical company dedicated to transforming chronic disease care through innovative, patient-centric solutions for cardiometabolic and orphan lung diseases, today announced that new clinical and real‑world data related to Afrezza® (insulin human) Inhalation Powder along with analyses of FUROSCIX® (furosemide injection) in patients with co-morbidities will be presented at the American Diabetes Association's (ADA) 2026 Scientific Sessions, taking place June 5-8, 2026, in New Orleans, Louisiana.

"As we approach the upcoming FDA target action date of Afrezza for pediatric patients, these new data further strengthen our understanding of inhaled insulin across a range of patient populations and clinical settings," said Dr. Ajay Ahuja, Chief Medical Officer for MannKind Corporation. "We are encouraged by the positive findings in both adult and pediatric populations, which reflect our ongoing commitment to advance meaningful real-world insights that can help individualize diabetes management, consistent with ADA guidelines."

Key highlights include:

  • Pediatric Efficacy & A1c: Subgroup analysis from the INHALE-1 study examining inhaled insulin versus rapid-acting analogs (RAA) in children and adolescents with diabetes and baseline HbA1c ≤9.5%, including 26-week A1c changes in CGM metrics.
  • Youth Treatment Satisfaction: Post hoc analysis from the INHALE-1 study evaluating patient-reported treatment satisfaction among children and adolescents with diabetes who achieved HbA1c <8% at 26 weeks, comparing inhaled insulin and RAA using a validated teen and parent survey.
  • AID Algorithm and Inhaled Insulin Use: Exploratory analysis of inhaled insulin used alongside automated insulin delivery (AID) systems, evaluating how different algorithms may affect glycemic outcomes when inhaled insulin is used for prandial and correction dosing
  • Inhaled Insulin in Gestational Diabetes: Randomized crossover study evaluating inhaled insulin compared with rapid-acting insulin analogs in individuals with gestational diabetes during controlled meal conditions. The analysis examines postprandial glucose responses and hypoglycemia outcomes in this patient population.

Additionally, MannKind will host booth #909 in the Exhibit Hall, showcasing the latest on inhaled insulin, including a virtual reality (VR) immersion experience that transports you through the lungs to experience mealtime insulin like never before.

Nine poster presentations at ADA 2026 include:

Saturday, June 6, 2026 – 12:30pm CT in Poster Hall (Halls D-E)

Exploratory Evaluation of Technosphere Insulin with Automated Insulin Delivery: Impact of Total Daily Dose Algorithms

Presenter: Joanne K Rinker, MS; MannKind

Efficacy and Safety of Inhaled Technosphere Insulin (TI) vs. Rapid-Acting Analog in Youth with HbA1c ≤9.5%: Subgroup Analysis from INHALE-1

Presenter: Kevin Kaiserman, MD; MannKind

Inhaled Insulin Assessment of Incident Lung Cancer Risk among Adults with Type 2 Diabetes (T2D) Compared with Other Therapies for Diabetes Using Real-World Evidence

Presenter: Kevin Kaiserman, MD; MannKind

Participants Achieving HbA1c <8% in Youth Report Greater Treatment Satisfaction with Inhaled Technosphere Insulin vs. Rapid‑Acting Analogs

Presenter: Joanne K Rinker, MS; MannKind

Inhaled Insulin Demonstrates Lower Variability and Faster Onset Compared with Subcutaneous Rapid-Acting Analogs

Presenter: Jennifer Nguyen, PharmD; MannKind

Sunday, June 7, 2026 – 12:30pm CT in Poster Hall (Halls D-E)

Inhaled Insulin Demonstrates Earlier Completion of Total Pharmacodynamic Effect Compared with Lispro

Presenter: Kevin Kaiserman, MD; MannKind

Impact of the Inflation Reduction Act on Afrezza Access: A Retrospective Review of TRx Distribution from Baseline Q4 2022 to Q1 2024

Presenter: Jennifer Nguyen, PharmD; MannKind

Inhaled Technosphere Insulin (TI) Compared with Rapid-Acting Analog Insulin (RAA) in Gestational Diabetes (GDM)

Presenter: Amy Valent, DO; Oregon Health & Science University

Monday, June 8, 2026 – 12:30pm CT in Poster Hall (Halls D-E)

Subcutaneous (SC) Furosemide (FUR) Use for Fluid Overload in Persons Living with Diabetes Mellitus

Presenter: Ajay Ahuja, MD; MannKind

Afrezza Pediatric Indication: FDA Review in Progress, Not Yet Approved

In October 2025, the FDA accepted for review a supplemental Biologics License Application (sBLA) for Afrezza in children and adolescents between the ages of 4-17 who are living with type 1 or type 2 diabetes, with a PDUFA target action date of May 29, 2026. If approved, it would be the first needle-free insulin option for pediatric patients in 100+ years of insulin therapy.

Afrezza was first approved by the FDA for adults (age 18+) in June 2014 and is also approved in India and Brazil. It is recognized as part of the American Diabetes Association's Standards of Care.